Gyre Therapeutics (GYRE) EBITDA (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly EBITDA of -$9.4 million for Q1 2026, down 511.57% year-over-year from $2.3 million in Q1 2025, and down 8027.97% quarter-over-quarter from $118000.0 in Q4 2025.
Gyre Therapeutics (GYRE) EBITDA (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported EBITDA for 17 consecutive years, with -$9.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 511.57% year-over-year to -$9.4 million; the TTM figure through Mar 2026 stood at -$141000.0 (down 101.36% YoY), while the FY2025 annual figure was $11.5 million, down 28.93% from the prior year.
- EBITDA retreated to -$9.4 million in Q1 2026 per GYRE's latest filing, from $118000.0 in the prior quarter.
- Across five years, EBITDA topped out at $51.5 million in Q2 2022 and bottomed at -$91.6 million in Q4 2023.
- Historically, EBITDA has averaged -$2.3 million across 5 years, with a median of $2.3 million in 2025.
- Annual changes were most pronounced in 2022 — EBITDA soared 358.76% — and 2026, when it sank 511.57%.
- Gyre Therapeutics' EBITDA stood at -$22.5 million in 2022, then slumped by 307.98% to -$91.6 million in 2023, then surged by 100.73% to $665000.0 in 2024, then slumped by 82.26% to $118000.0 in 2025, then tumbled by 8027.97% to -$9.4 million in 2026.
- Business Quant data shows GYRE's EBITDA at -$9.4 million in Q1 2026, $118000.0 in Q4 2025, and $6.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | -14.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.36 Mn |
| Mar 31, 2026 | -9.36 Mn |
| Dec 31, 2025 | 118,000.00 |
| Sep 30, 2025 | 6.93 Mn |
| Jun 30, 2025 | 2.17 Mn |
| Mar 31, 2025 | 2.27 Mn |
| Dec 31, 2024 | 665,000.00 |
| Sep 30, 2024 | 4.23 Mn |
| Jun 30, 2024 | 3.19 Mn |
| Mar 31, 2024 | 8.07 Mn |
| Dec 31, 2023 | -91.63 Mn |
| Sep 30, 2023 | 12.76 Mn |
| Jun 30, 2023 | 4.97 Mn |
| Mar 31, 2023 | 6.66 Mn |
| Dec 31, 2022 | -22.46 Mn |
| Sep 30, 2022 | -5.17 Mn |
| Jun 30, 2022 | 51.53 Mn |
| Mar 31, 2022 | -14.70 Mn |
| Dec 31, 2021 | -20.31 Mn |
| Sep 30, 2021 | -25.23 Mn |